Kornimate/medical-research-clean huggingface dataset:
evaluation of visual outcomes after myopic lasik

Conditions: Myopia; Astigmatism; Myopic Astigmatism

Summary: the aim of the study was to evaluate visual outcomes, contrast sensitivity, glare testing and high order aberrations induced by different laser technologies and to evaluate differences in aberrometer technology. we hypothesized that there will not be differences among conventional or wavefront guided treatments.

the aim of the study was to evaluate and compare visual outcomes, contrast sensitivity, glare testing and induction of high order aberrations by different laser technologies and to evaluate differences in aberrometer technology.

Eligibility criteria:
inclusion criteria: * 18 years or older * candidates for bilateral lasik * myopic range: 0.00 to -7.00 d * astigmatism: 0.00 to -5.00 d exclusion criteria: * pupil size greater than 8mm diameter, infrared measurement * thin corneas (preoperatively calculated minimal residual bed \< 250 um) * irregular astigmatism * asymmetric astigmatism * unstable refraction * other criteria that preclude the patient to undergo lasik
trivalent rha dose escalation study in elderly subjects

Conditions: Influenza

Summary: this study will compare the safety and immunogenicity of three different dose levels of an experimental recombinant influenza ha protein vaccine to a standard inactivated influenza vaccine in heallthy elderly subjects ages 65-80. blood and nasal secretions for assessment of antibody responses will be obtained from all subjects prior to and one month after vaccination.

approximately 400 healthy, ambulatory adults ages 65-80 will be randomized into one of four study groups to receive a single immunization of a licensed trivalent inactivated influenza vaccine or one of three dose levels of an investigatioanl trivalent recombinant influenza ha protein vaccine. the study will be conducted in 2 stages. in the first stage, 80 subjects will be randomized (20 per group) and receive one vaccination on day 0. safety will be evaluated after stage 1 subjects have completed a 7 day follow-up. enrollment of stage 2 subjects will begin after the safety data for stage 1 has been reviewed. in stage 2, 320 subjects will be randomized (80 per group) and receive one vaccination on day 0. blood and nasal secretions will be collected prior to an approximately one month after vaccination to assess antibody responses.

Eligibility criteria:
inclusion criteria: * medically stable adult age 65 -80. * able to give informed consent. * able to comply with all study procedures. * community dwelling. exclusion criteria: * history of immunodeficiency or treatment with immunosuppressive medications. (use of inhaled steroids or of topical steroids is not considered immunosuppressive). * allergy to eggs, egg proteins, thimerosal, or other vaccine components. * acute febrile illness or upper respiratory tract illness within 72 hours of vaccination. * life expectancy less than 6 months. * use of experimental vaccines or medications within one month of study entry. * receipt of parenteral immunoglobulin within one month of study entry. * any acute or chronic condition which in the opinion of the investigator would render vaccination unsafe or interfere with the evaluation of response.

Keywords: influenza, baculovirus, immunogenicity, geriatrics
effects of low power laser therapy on muscle performance isokinetic pre-exercise in individuals with diabetes mellitus type ii

Conditions: Diabetes Mellitus Non-insulin-dependent

Summary: the low level laser therapy is able to improve immediately and long term (after 4 weeks of treatment, 3 days per week resulting in 12 applications of low level laser therapy) isokinetic muscle performance of the quadriceps femoris muscle (peak torque, total muscular work , maximum power and fatigue index - normalized by body weight) pre-exercise concentric isokinetic quadriceps femoris muscle in subjects with diabetes mellitus non-insulin-dependent.

the low level laser therapy is able to improve after 4 weeks of treatment, 3 days per week resulting in 12 applications of low level laser therapy, the indicators: the low level laser therapy is able to improve immediately and long term (after 4 weeks of treatment, 3 days per week resulting in 12 applications of low level laser therapy), the indirect blood markers for muscle damage that evaluate the enzymatic activity of creatine kinase (ck) and lactate dehydrogenase (ldh) and the visual analog scale (vas-f) for fatigue, improves indicators f 2.2 point of the whoqol-100 for fatigue, improvement in functional indicators of the lower lower extremity functional regarding scale, functional improvement in performance in the execution of the test stand and sit and walk test six minutes, the indicators for quality improvement of life questionnaire for the diabetes quality of life measure and emotional states through the questionnaire problems areas in diabetes scale. eligibility criteria: diagnosis for diabetes mellitus non-insulin-dependent confirmed by the individual physician, presenting between 30 to 70 years.exclusion criteria: diagnosis of cardiovascular disorders, diagnosis of diabetic neuropathy, which have a skin lesion or local infection (quadriceps), history of musculoskeletal injuries in the last 6 months or during the study, individuals unable to perform the assessment protocols / exercise so satisfactory, those who are doing some kind of regular physical activity and who underwent alcohol intake in the 24 hours before any of the stages of the study.

Eligibility criteria:
inclusion criteria: * diagnosis for diabetes mellitus non-insulin-dependent * age between 30 to 70 years exclusion criteria: * diagnosis of cardiovascular disorders * diagnosis of diabetic neuropathy, * skin lesion or local infection (quadriceps) * history of musculoskeletal injuries in the last 6 months or during the study * individuals unable to perform the assessment protocols or exercise * regular physical activity * underwent alcohol intake in the 24 hours before any of the stages of the study

Keywords: diabetes mellitus non-insulin-dependent low level laser therapy
oct and oct-a deep learning in diabetic patients wiht artificial pancreas device

Conditions: Type 1 Diabetes Mellitus With Artificial Pancreas Device

Summary: this study evaluates the ability of deep learning to improve the knowledge about structural and vascular retinal changes in diabetic patients undergoing artificial pancreas device, using optical coherence tomography angiography.

hybrid artificial pancreas systems (csii) are able to adjust the type 1 diabetic patient's glycemic levels with insulin doses appropriate to the patient's blood glucose. the optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. the study evaluates the changes in optical coherence tomography angiography features in diabetic patients undergoing artificial pancreas device, elaborating these data with artificial intelligence.

Eligibility criteria:
inclusion criteria: * • age older than 18 years * diagnosis of type 1 diabetes * treatment with artificial pancreas device * absence of previous ocular surgery and congenital eye diseases. * absence of errors of refraction * absence of lens opacities * absence of low-quality oct and octa images exclusion criteria: * age younger than 18 years * previous ocular surgery and congenital eye diseases * errors of refraction * lens opacities * low-quality oct and octa images
the impact of ketamine gargling on the incidence of post intubation sore throat

Conditions: Postoperative Sore Throat

Summary: tracheal intubation often causes trauma to the airway mucosa, leading to postoperative sore throat (post), which has been reported to occur in 21-65% of cases. while considered a minor complication, post can contribute to postoperative discomfort and patient dissatisfaction.

patients have ranked post as the eighth most adverse effect during the postoperative period. various methods, both non-pharmacological and pharmacological, have been explored to mitigate post with varying degrees of success. non-pharmacological approaches include using smaller-sized endotracheal tubes, lubricating the tube with water-soluble jelly, employing careful airway instrumentation, ensuring intubation after full relaxation, employing gentle oropharyngeal suctioning, minimizing intracuff pressure, and deflating the tracheal tube cuff completely before extubation, all of which have been reported to reduce the incidence of post.

Eligibility criteria:
inclusion criteria: * adult patients from both sex and aged between 18 and 45 years. * all participants were scheduled for elective laparoscopic appendectomy or cholecystectomy under general anesthesia. * classified as asa (american society of anesthesiologists) i or ii. * intubation duration is less than 90 minutes. exclusion criteria: * patients classified as asa iii or higher. * patients exhibiting symptoms of sore throat prior to entering the operating room, or presenting with any respiratory illness or signs of respiratory infection. * patients who smoke. * patients with a history of allergy to drugs used in this study. * patients who are addicted to steroid drugs (inhaled or oral). * patients with predicted difficult airway and intubation, indicated by a mallampati score of ii or higher. * obese patients with a bmi exceeding 35. * patients with neurological diseases.

Keywords: ketamine gargling post-operative sore throat endotracheal tube complications
person-environment fit for persons with dementia

Conditions: Dementia Alzheimers; Alzheimer Disease

Summary: this trial will assess feasibility of a non-pharmacological intervention for persons living with alzheimer's disease and related dementias (adrd) to improve behavioral and psychiatric symptoms of dementia and functional performance. using a two-arm, prospective randomized controlled trial, 38 dyads (person with adrd and caregiver) will complete an 8-week telehealth occupational therapy intervention provided via zoom with caregivers and persons with dementia or receive an active control with 8 telehealth sessions to discuss publicly available caregiver education with a non-clinical research assistant.


Eligibility criteria:
inclusion criteria: participants with dementia * men or women aged 60-99, inclusive. * living at home in the community with one primary caregiver. * diagnosis or probably diagnosis of dementia (confirmed by clinical dementia rating scale score of 1.0+) * if on psychotropic medication, they are at a point where dosage and treatment are stabilized for the duration of the study. * functional sensory abilities with or without aids (hearing, vision, smell, touch, taste) * caregiver report of challenges related to behaviors within 4 weeks of study enrollment. * caregiver willing to participate throughout duration of study. * contact with university of kentucky alzheimer's disease research center or kentucky neuroscience institute medical provider within 12 months of study recruitment. inclusion criteria: caregiver for participants with dementia * men or women aged 21-99, inclusive. * willingness to participate in study and implement recommended data collection tools. * english speaking, able to read and write. * ability to retrieve and send mail. exclusion criteria: participants with dementia * unstable medical conditions within one month prior to screening visit such as poorly controlled blood pressure, diabetes, current cancer diagnosis, or breathing problems, etc. * wheelchair or bed bound. * residence in skilled nursing facility or facility-based care. * caregiver report of physically violent behaviors. * initiation of antipsychotic medication within 4 weeks prior to screening or unpredictable use of such medications * diagnosis of profound or total sensory altering disorders including macular degeneration, legal blindness, total deafness, severe peripheral neuropathy, anosmia. * major depression in past 12 months (dsm-iv criteria), major mental illness such as schizophrenia, bipolar disorder, personality disorders, or recent (in past 12 months) alcohol or substance abuse. * major infection within 4 weeks prior to the baseline visit. exclusion criteria: caregiver for participant with dementia: • diagnosis of mild cognitive impairment or dementia.

Keywords: behavioral occupational therapy alzheimer's disease and related dementias telehealth caregiver
esmadem education model on high-risk pregnant women

Conditions: Risky Pregnancies

Summary: pregnancy is a normal and natural process in a woman's life. during this process, anatomical, physiological, biochemical and emotional changes are observed. during pregnancy, sometimes risk situations arise from the mother, sometimes from the fetus. the scope of prenatal care is high today, the main focus is on the physical aspects of care and medical measures. midwives who provide holistic care should also address spiritual care. therefore, the esmadem education model will be conducted to examine the effect of the spiritual coping, tolerance and depression of risky pregnancies.


Eligibility criteria:
inclusion criteria: pregnant women aged 18-45 ,in the second trimester, primiparous, have sufficient communication skills, literate, can read and understand turkish, agree to participate in the research continuing pregnancy school having a risky pregnancy diagnosis according to the criteria in the ministry of health pregnancy risk assessment form and having been diagnosed as a risky pregnancy by a physician exclusion criteria: * having any mental illness

Keywords: risky pregnancies education spiritual depression
position changes in cirrhosis hemorrhagic spot detection

Conditions: Emergency Hemostasis

Summary: the patients who conducted position change due to massive egvb resulting in poor visualization in the stomach were included. those with incomplete information were excluded. the patients were characterized in terms of age, sex, causes of liver cirrhosis, adverse events (aes) during position change, additional findings after body position change, treatment regimens and follow-up information.

the patients who conducted position change due to massive egvb resulting in poor visualization in the stomach were included. those with incomplete information were excluded. the patients were characterized in terms of age, sex, causes of liver cirrhosis, adverse events (aes) during position change, additional findings after body position change, treatment regimens and follow-up information. the gastroscopes procedure was started in the left lateral position in all patients. bleeding varices detected before the position change were stopped by the endoscopic hemostatic measures described above. the following conditions would consider a change of position during gastroscopy: (1) a large amount of blood or blood clot was found after reaching the stomach, making it difficult to suction adequately which led to poor mucosal visuality; (2) persistent massive bleeding from a blood vessel that filled the stomach cavity rapidly after suction, making it impossible to clarify the bleeding vessel.during position changing procedure, endoscopist withdrew the gastroscope from the stomach and patients changed from the left lateral position to the right lateral position with the help of the nurses. then endoscopist reinserted the gastroscope into the stomach and tried to detect the addition varices after position change. bleeding varices were treated by injection of n-butyl-cyanoacrylate glue (glub b or beltran, compex) or/and lauromacrogol (shanxi, tianyu).

Eligibility criteria:
inclusion criteria: * conducted position change due to massive egvb resulting in poor visualization in the stomach exclusion criteria: * incomplete information

Keywords: complications of cirrhosis variceal bleeding position change emergency hemostasis rebleeding
kinetics of cevs over the 24-hour dosing interval after low-dose aspirin administration

Conditions: Cardiovascular Diseases; Vesicle

Summary: extracellular vesicles (evs) are small vesicles deriving from all cell types during cell activation, involved in transcellular communication, and regarded as predictors of vascular damage and of cardiovascular events. the investigators will test the hypothesis that, in patients on chronic low-dose aspirin treatment for cardiovascular prevention, aspirin may affect the release of evs within the 24 hours interval.


Eligibility criteria:
inclusion criteria: * patients on low-dose aspirin treatment for cardiovascular prevention for at least 1 month * arterial hypertension if well controlled with stable drug therapy * hypercholesterolemia if well controlled with stable drug therapy exclusion criteria: * cigarette smoking insufficiency * clinically significant hepatic insufficiency * clinically significant renal insufficiency * clinically significant cardiac insufficiency * clinically significant pulmonary insufficiency * history of malignant neoplasms (diagnosed and treated within the past 5 years) * pregnancy or lactation * history of malabsorption * regular (daily) alcohol consumption * regular (i.e., more than 3 days per week) non steroidal anti-inflammatory drug intake * type 1 diabetes excluded by islet autoantibodies evaluation (anti-glutamic acid decarboxylase, islet cell cytoplasmic, and ia-2 antibodies), family history of type 1 diabetes, age lower than 40 years, lean phenotype, early requirement for insulin therapy

Keywords: circulating extracellular vesicles aspirin
meal handling of advanced closed loop insulin delivery.

Conditions: Type 1 Diabetes

Summary: the study will compare meal related glycemic indices following 2 types of meal announcement: 1. conventional assessment of carb content plus carb equivalence of proteins and fat 2. algorithm device optimal universal meal announce equivalent


Eligibility criteria:
inclusion criteria: 1. subject is 20 to 70 years of age at time of screening 2. subject's weight is between 50 and 120 kg 3. a clinical diagnosis of type 1 diabetes as determined by the investigator for a minimum of 36 months prior to enrollment 4. subject has ongoing use of an insulin pump and rtcgm ≥ 6 months prior to screening 5. current use of 670g 4.0 pump 6. subject has an a1c value ≤ 10.0% demonstrated at the time of enrollment. 7. subject uses a rapid-acting analogue insulin in his/her pump 8. patient is willing to undergo all study procedures 9. english proficiency 10. minimum daily insulin requirement (total daily dose) of greater than or equal to 8 units exclusion criteria: 1. female subject who has a positive serum pregnancy screening test, or who plans to become pregnant during the course of the study 2. subject has unresolved adverse skin condition, or unable to tolerate tape adhesive, in the area of sensor placement or device replacement (e.g., psoriasis, rash, staphylococcus infection) 3. subject has a history of hypoglycemic seizure or hypoglycemic coma within the past 12 months 4. subjects currently taking adjunct therapy with sglt2-inhibitors, amylin. 5. subject has a history of seizure disorder unrelated to diabetes within the past 12 months 6. gastroparesis, uncontrolled thyroid disorder, addison disease,. , pituitary insufficiency 7. subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (tia), cerebrovascular accident (cva), congestive heart failure, ventricular rhythm disturbances, or thromboembolic disease within the past 6 months 8. subject has a presence of a cardiac pacemaker or any other device that may be sensitive to radio frequency telemetry 9. subject has any condition, including screening lab values that in the opinion of the investigator may preclude him/her from participating in the study and completing study related procedures 10. subject is actively participating in other investigational study (drug or device) 11. subjects who consume alcohol daily 12. use of cgm (other than per protocol) throughout the duration of the study 13. use of hydroxyurea medication
an exploratory investigation of a supplement to enhance sleep quality and quantity

Conditions: Sleep; Sleep Disturbance; Sleep Hygiene

Summary: this double-blind study will examine the effectiveness of dream powder and dream powder extra strength over a six week period. the main outcomes of interest will be sleep quantity and quality, as well as self-reported changes in sleep across the study period.


Eligibility criteria:
inclusion criteria: * self-reported issues with sleep must be in good overall health with no unstable medical conditions must own a wearable sleep tracker (i.e., apple watch, "fitbit", "whoop", etc.) must be willing to discontinue any supplements meant to assist with sleep. exclusion criteria: * females who are pregnant or breastfeeding diagnosis of insomnia or sleep apnea taking a prescription medication that affects sleep anyone with a pre-existing condition that would prevent them from adhering to the protocol anyone with a known history of past severe allergic reactions

Keywords: sleep sleep disturbance sleep quality sleep quantity
tms for post stroke depression

Conditions: Post-stroke Depression

Summary: the purpose of this study is to find alternative treatments for patient's suffering from depression after having a stroke.this study aims to show that accelerated rtms is a safe, effective,and convenient treatment for patient's suffering from post-stroke depression in the acute to subacute phase. this will be an open label trial and thus all participants will receive the active rtms intervention.

the primary objectives of this project are as follows: 1. to assess the efficacy tms in psd. we hypothesize that there will be a decrease in the hamd score in patients receiving tms 2. to assess the feasibility of an accelerated protocol using rtms in patients with acute to subacute stroke and co-existing psd. we hypothesize that the accelerated protocol will promote compliance in our patient population and that the administration of this intervention is feasible. 3. to assess the safety of rtms in patients with acute to subacute stroke. we hypothesize that the side effects of tms will be minimal and the therapy will be well-tolerated and safe in individuals with recent strokes and co-existing psd.

Eligibility criteria:
inclusion criteria: * between the ages of 22-85 years old * radiographic evidence of acute or subacute stroke * ischemic stroke diagnosed within the last 2 weeks to 6 months * hamd depression score 8 or greater * able to provide written informed consent * agree to participate in all study procedures exclusion criteria: * metallic objects or neurostimulators implanted intracranially * stroke in the area of stimulation * current thoughts of si or self-harm as assessed by the m.i.n.i. suicide scale score \> 8 * asrm (altman self rating mania scale) score \> 6 (6 or above indicates likelihood of manic symptoms) * current use of illicit substances * known history of epilepsy or seizure disorder * clinically significant ekg abnormalities including qtc prolongation \>450 ms in men or \>480 ms in women